Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast

Executive Summary

Solid US demand for Gonal-f fertility and Rebif MS drugs in the second quarter – along with commissions from its Xalkori co-promotion partnership there with Pfizer – let Merck KGaA upgrade its guidance for the full year.

Advertisement

Related Content

Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Interview: German Merck Set For Big "Leap" In India
German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space
German Merck To Double Fund Size And Broaden Corporate VC Focus

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel